{"id":143040,"date":"2023-02-28T10:30:00","date_gmt":"2023-02-28T15:30:00","guid":{"rendered":"https:\/\/44.250.171.167\/?p=143040"},"modified":"2023-02-28T10:55:07","modified_gmt":"2023-02-28T15:55:07","slug":"earnings-summary-of-jubilant-pharmova-limited-for-q3-fy23","status":"publish","type":"post","link":"https:\/\/alphastreet.com\/india\/earnings-summary-of-jubilant-pharmova-limited-for-q3-fy23\/","title":{"rendered":"Earnings Summary Of Jubilant Pharmova Limited For Q3 FY23"},"content":{"rendered":"<p>Jubilant Pharmova Limited (NSE: JUBLPHARMA) was formerly known as Jubilant Life Sciences Limited and changed its name to Jubilant Pharmova Limited in November 2020. The company was founded in 1978 and is headquartered in Noida, India. It has a presence in over 100 countries worldwide and operates through several subsidiaries such as Jubilant Generics, Jubilant HollisterStier, Jubilant Radiopharma, and Jubilant Pharma.<\/p>\n<p>For the quarter ended December 31, 2022, Jubilant Pharmova reported a consolidated Revenue of \u20b91533.22 crore, which represents an increase of 18% YoY. The company&#8217;s Radipharma segment for the quarter stood at \u20b9613.21 crore, up 20% YoY, meanwhile the Net loss after tax was \u20b916.04 crore. The Sterile Injectibles segment reported a revenue of \u20b9295.32 crore, which remained same YoY. The Contract Manufacturing of Sterile Injectables segment reported a revenue of \u20b9300.57 crore, up 13.6% YoY.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Jubilant Pharmova Limited (NSE: JUBLPHARMA) was formerly known as Jubilant Life Sciences Limited and changed its name to Jubilant Pharmova Limited in November 2020. The company was founded in 1978 and is headquartered in Noida, India. It has a presence in over 100 countries worldwide and operates through several subsidiaries such as Jubilant Generics, Jubilant [&hellip;]<\/p>\n","protected":false},"author":1917,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"jetpack_post_was_ever_published":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[392],"tags":[1115],"class_list":["post-143040","post","type-post","status-publish","format-standard","hentry","category-earnings","tag-pharmaceuticals"],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_likes_enabled":false,"jetpack-related-posts":[{"id":140011,"url":"https:\/\/alphastreet.com\/india\/jubilant-pharmova-limited-q3-fy23-revenue-increased-by-18\/","url_meta":{"origin":143040,"position":0},"title":"Jubilant Pharmova Limited Q3 FY23; Revenue Increased By 18%","author":"Hardik Bhandare","date":"February 3, 2023","format":false,"excerpt":"Jubilant Pharmova Limited (NSE: JUBLPHARMA) reported a Revenue from Operations of \u20b91,533.22 Crores, a boost of 18% growth from the previous year. The Net Loss for the business is \u20b916.04 Crore from the profit of \u20b950.80 Crore year on year. Earnings per Share is -\u20b90.98 for this quarter.","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/02\/1b64d801-cd27-48d3-b10b-07257f0871c5-scaled.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/02\/1b64d801-cd27-48d3-b10b-07257f0871c5-scaled.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/02\/1b64d801-cd27-48d3-b10b-07257f0871c5-scaled.jpg?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/02\/1b64d801-cd27-48d3-b10b-07257f0871c5-scaled.jpg?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/02\/1b64d801-cd27-48d3-b10b-07257f0871c5-scaled.jpg?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/02\/1b64d801-cd27-48d3-b10b-07257f0871c5-scaled.jpg?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":168645,"url":"https:\/\/alphastreet.com\/india\/jubilant-pharmova-ltd-q4fy25-10-rise-in-revenue\/","url_meta":{"origin":143040,"position":1},"title":"Jubilant Pharmova Ltd Q4FY25; 10% rise in Revenue","author":"Chirag Gupta","date":"June 4, 2025","format":false,"excerpt":"Jubilant Pharmova Ltd is an integrated global pharmaceuticals company having three business segments i.e. pharmaceuticals, contract research and development services and proprietary novel drugs. Financial Results: Jubilant Pharmova Ltd reported Revenues for Q4FY25 of \u20b91,929.00 Crores up from \u20b91,759.00 Crore year on year, a rise of 9.66%. Total Expenses for\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/06\/2-1.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/06\/2-1.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/06\/2-1.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/06\/2-1.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/06\/2-1.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/06\/2-1.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":147963,"url":"https:\/\/alphastreet.com\/india\/jubilant-pharmova-q4fy23-earnings-story\/","url_meta":{"origin":143040,"position":2},"title":"Jubilant Pharmova Q4FY23 Earnings Story","author":"Karan_Singh","date":"June 1, 2023","format":false,"excerpt":"The three business components of Jubilant Pharmova Ltd, which include medicines, contract research and development services, and patented new therapies, make up this integrated global pharmaceuticals corporation. Financial Results: Jubilant Pharmova Ltd. reported Total Income for Q4FY23 of \u20b9 1,683 Crores up from \u20b9 1,525 Crore year on year, a\u2026","rel":"","context":"In &quot;Earnings&quot;","block_context":{"text":"Earnings","link":"https:\/\/alphastreet.com\/india\/category\/earnings\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/01\/iStock-1345489729.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/01\/iStock-1345489729.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/01\/iStock-1345489729.jpg?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/01\/iStock-1345489729.jpg?resize=700%2C400&ssl=1 2x"},"classes":[]},{"id":161673,"url":"https:\/\/alphastreet.com\/india\/jubilant-pharmova-ltd-q4fy24-5-rise-in-revenue\/","url_meta":{"origin":143040,"position":3},"title":"Jubilant Pharmova Ltd Q4FY24; 5% rise in Revenue","author":"Chirag Gupta","date":"May 29, 2024","format":false,"excerpt":"Jubilant Pharmova Ltd is an integrated global pharmaceuticals company having three business segments i.e. pharmaceuticals, contract research and development services and proprietary novel drugs. Financial Results: Jubilant Pharmova Ltd reported Revenues for Q4FY24 of \u20b91,759.00 Crores up from \u20b91,678.00 Crore year on year, a rise of 4.83%. Total Expenses for\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/05\/image-212.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/05\/image-212.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/05\/image-212.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/05\/image-212.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/05\/image-212.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/05\/image-212.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":158356,"url":"https:\/\/alphastreet.com\/india\/jubilant-pharmova-ltd-q3fy24-8-rise-in-revenue\/","url_meta":{"origin":143040,"position":4},"title":"Jubilant Pharmova Ltd Q3FY24; 8% rise in Revenue","author":"Chirag Gupta","date":"February 2, 2024","format":false,"excerpt":"Jubilant Pharmova Ltd is an integrated global pharmaceuticals company having three business segments i.e. pharmaceuticals, contract research and development services and proprietary novel drugs. Financial Results: Jubilant Pharmova Ltd reported Revenues for Q3FY24 of \u20b91,677.00 Crores up from \u20b91,552.00 Crore year on year, a rise of 8.05%. Total Expenses for\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/02\/image-24.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/02\/image-24.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/02\/image-24.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/02\/image-24.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/02\/image-24.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/02\/image-24.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":166648,"url":"https:\/\/alphastreet.com\/india\/jubilant-pharmova-ltd-q3fy25-53-rise-in-profits\/","url_meta":{"origin":143040,"position":5},"title":"Jubilant Pharmova Ltd Q3FY25; 53% rise in Profits","author":"Chirag Gupta","date":"February 4, 2025","format":false,"excerpt":"Jubilant Pharmova Ltd is an integrated global pharmaceuticals company having three business segments i.e. pharmaceuticals, contract research and development services and proprietary novel drugs. Financial Results: Jubilant Pharmova Ltd reported Revenues for Q3FY25 of \u20b91,822.00 Crores up from \u20b91,677.00 Crore year on year, a rise of 8.65%. Total Expenses for\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/02\/2-1.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/02\/2-1.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/02\/2-1.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/02\/2-1.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/02\/2-1.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/02\/2-1.png?resize=1400%2C800&ssl=1 4x"},"classes":[]}],"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/143040","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/users\/1917"}],"replies":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/comments?post=143040"}],"version-history":[{"count":0,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/143040\/revisions"}],"wp:attachment":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media?parent=143040"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/categories?post=143040"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/tags?post=143040"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}